We prepared several novel molecular transporters built on myo-and scyllo-inositol scaffolds with variations in the number of guanidine residues, linker chain lengths and patterns. Some of these transporters were found to localize in mitochondria, and the mitochondrial affinity seems to be substantially related to the scaffold stereochemistry.
Introduction
Efficient drug delivery and good bioavailability at target tissues are important factors in the new drug development, because many drug candidates with promising in vitro activity fail or find only limited applications due to poor absorption, distribution, metabolism or excretion (ADME) profiles. Highly desired are novel molecular transporters that can help a promising drug candidate to be taken up by cells and delivered to the desired organelles or tissues. In this connection, substantial research efforts have been extended to several classes of cellpenetrating peptides (CPPs) such as HIV-1 Tat protein. CPPs and related peptides have been extensively studied for their potential utilities as delivery vehicles in order to enhance pharmacological properties of drugs having poor bioavailability, including small molecules, proteins, genes, etc. [1] [2] [3] [4] [5] However, the CPPs have a number of limitations, including instability toward endogenous peptidases, immunogenic liability, inter-tissue permeation despite their interesting in vitro characteristics. In efforts to improve upon these limitations, several different types of synthetic molecular transporters (MTs), e.g. peptoids, 6 oligocarbamates, 7 β-peptides, 8 peptide nucleic acids, 9 and others [10] [11] [12] [13] have been investigated. Recently we have explored novel classes of synthetic molecular transporters, in which multiple units of the guanidine functionality are attached through linear or branched chain carboxylate linkers to various scaffolds such as inositol dimers, sorbitol, lactose, and sucrose. [14] [15] [16] [17] Many of these MTs exhibited good cellular uptake properties, and moreover diverse intracellular organellar and tissue selectivity was observed somewhat unexpectedly. For example, several G8 (containing eight guanidine residues) molecular transporters based on the sorbitol scaffold and branched chain linkers showed intracellular selectivity, namely a good affinity toward mitochondria in HeLa as well as CD34
+ stem cell-like KG1a leukaemia cells. 15 This observation was deemed highly interesting because of their potential as mitochondria selective delivery vectors, especially in view of a dearth of viable mitochondrial transporters. [18] [19] [20] It is now recognized that mitochondria play essential roles in many intractable neural and neuromuscular diseases such as familial amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Huntington's disease, as well as in apoptosis and aging. [21] [22] [23] [24] [25] In addition, the sorbitol-based G8 transporters also displayed more affinity for heart muscle and brain sections in mice than any other tissues examined. Studies with lactose-based G7 molecular transporters 16 and sucrose-based G7 molecular transporters 17 showed that the mitochondrial affinity and the organellar distribution pattern in general appear to be related to the charge (number of guanidine residues), the nature of scaffold, flexibility and lipophilicity of the linker chains, and even the cargo attached. In order to better understand the structure-property relationships with a particular focus on the mitochondrial affinity, we have now studied the effect of the scaffold stereochemistry in a series of G8 molecular transporters built on two inositol stereoisomers, namely myo-and scyllo-inositols.
Experimental

Synthesis.
General methods: All non-hydrolytic reactions were carried out in oven-dried glassware under an inert atmosphere of dry argon or nitrogen. All commercial chemicals were used as received except for solvents, which were purified and dried by standard methods prior to use. Analytical TLC was performed on a Merck 60 F254 silica gel plate (0.25 mm thickness) and analytical reverse-phase TLC on a Merck RP-8 F254s, and visualization was done with UV light (254 nm and 365 nm), and/or by spraying with a 5% solution of phosphomolybdic acid or ninhydrin, followed by charring with a heat gun. Column chromatography was performed on Merck 60 silica gel (70 -230 or 230 -400 mesh), and MPLC was performed on Fluka 100 C8-reversed phase silica gel. Melting points were determined on a Thomas-Hoover MP apparatus and uncorrected. NMR spectra were recorded on a Bruker DPX 300 ( 1 H-NMR at 300MHz; 13 C-NMR at 75 MHz) and Bruker DRX 500 ( 1 H-NMR at 500 MHz; 13 C-NMR at 125MHz) spectrometers. Tetramethysilane was used as reference, and the chemical shift were reported in δ ppm and the coupling constant in Hz. Analytical HPLC was performed on Agilent 1100-HPLC Chemstation with an analytical column ZORBAX SB-C8 (5 μm, 4.6 mm ID × 25cm). Low resolution mass spectra were determined on a Micromass PLAT-FORM ll (EI and FAB). High resolution mass spectra were done on a JMS-700 at Korea Basic Science Institute (Daegu), and MALDI-TOF mass spectra on a Voyager-DE STR system at POSTECH. The standard extractive work-up procedure consisted of pouring into a large amount of water, extracting thoroughly with the organic solvent indicated, washing the combined extract successively with water and brine, drying the extract over anhydrous Na2SO4 or MgSO4, and evaporating the solvent. 3 and brine. The organic phase was dried and concentrated. The crude product was purified by column chromatography on silica gel (CH2Cl2:MeOH = 9:1) to afford compound 9a as a sticky solid (314 mg, 92%). A representative procedure for the removal of the N-benzyloxycarbonyl (Cbz) group -A mixture of compound 9a (150 mg, 0.044 mmol) in a mixed solvent of CH 2 Cl 2 :MeOH (1:9, 5 mL) was hydrogenated (40 psi) at rt over 10% Pd/C (30 mg). After 24 h, the catalyst was filtered through a celite bed and the filtrate was evaporated to afford free amine 10a (141 mg, 98%) as an off-white foamy solid. A representative procedure for the removal of the N-Boc group -A solution of 11a (160 mg crude) in gaseous HCl saturated ethyl acetate was stirred at rt for 24 h. The solution was concentrated and repeatedly washed with ethyl acetate and ether, and evaporated to give the crude product, which was purified by MPLC on Fluka 100 C8-reversed phase silica gel (CH 3 CN: H 2 O = 1:1, containing 0.1% TFA in both CH 3 CN and H 2 O). After freeze drying, compound 1a (as HCl-salt) was obtained (40 mg, 40% over two steps). 27 (9.96 g, 35.05 mmol) and p-TSA (3.33 mg, 17.5 mmol) in DMF (110 mL) at rt, was added dropwise 2-methoxypropene (33.5 mL, 350 mmol). After 1day, the reaction mixture was poured into aq. NaHCO 3 with vigorous stirring, and extracted with EtOAc. The organic layer was dried, concentrated, diluted with EtOAc (100 mL), and filtered to give compound 14a (2.9 g, 22.8%), and the filtrate was evaporated and chromatographed on silica gel to give compounds 14b (1.4 g, 11.5%). 14a : Rf 0. 25 , and DMAP (7 mg, 0.057 mmol) in CH 2 Cl 2 (1.5 mL) was stirred at rt under N 2 for 48 h. The reaction mixture was diluted with CH2Cl2, washed several times with H2O, NaHCO3 and brine. The organic phase was dried and concentrated to give the crude product, which was purified on silica gel (CH 2 -4-O-(6-aminohexanoyl)-2,3,5,6-tetra-O-[6-[bis-(3-N,N'-di-Boc-guanidino-propyl)-amino] -hexanoyl]-scyllo-inositol (18a): A mixture of compound 17a (150 mg, 0.0444 mmol) in a mixed solvent of CH 2 Cl 2 : MeOH (1:9, 5 mL) was hydrogenated (40 psi) at rt over 10% Pd/C (30 mg). After 24 h, the catalyst was filtered through celite and the filtrate was evaporated to afford free amine 18a (141mg, 98%) as an offwhite foamy solid. (15 μL, 0.105 mmol) , and the reaction mixture was stirred for 24 h at rt in dark. The reaction mixture was concentrated, diluted with ethyl acetate, and washed with water. Organic phase was dried and concentrated to give the crude product 19a (130 mg) as a yellow sticky glass, which was directly used in the next step. 
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1-O-Benzoyl-4-O-[6-(N-fluoresceinyl-5-thioureido)-hexanoyl]-2,3,5,6-tetra-O-[6-{bis-(3-guanidino-propyl)-amino}-hexanoyl]-scyllo-inositol (2a):
A solution of 19a (130 mg crude) in gaseous HCl saturated ethyl acetate was stirred at rt for 24h. The solution was concentrated and repeatedly washed with ethyl acetate and ether, and the crude product was purified by MPLC on Fluka 100 C8-reversed phase silica gel (CH 3 CN: H2O = 1:1, containing 0.1% TFA in both CH3CN and H2O). Upon freeze drying compound 2a (HCl-salt) was obtained as a greenish yellow foamy solid (30 mg, 37% over two steps). UV (H2O): λmax(ε) = 497 nm (30416 cm -1 M analytical HPLC: tR = 3.588 min (flow rate 1 mL/min; UV: λ = 220 nm; H 2 O:CH 3 CN = 70:30 with 0.1% TFA), purity > 95%. 
1-O-Benzoyl-4-O-[6-(N-fluoresceinyl-5-thioureido)-hexanoyl]-2,3,5,6-tetra-O-[8-{bis-(3-guanidino-propyl)-amino}-octanoyl]-scyllo-inositol (2b)
1-O-Benzoyl-2-O-(6-N-Cbz-aminohexanoyl)-3,4,5,6-tetra-O-benzyl-scyllo-inositol (21):
A solution of compound 20 27 (250 mg, 0.388 mmol), 6-N-Cbz-aminohexanoic acid (150 mg, 0.565 mmol), EDC (110 mg, 0.565 mmol) and DMAP (14 mg, 0.14 mmol) in CH 2 Cl 2 (4 mL) was stirred for 24 h at rt under N 2 . The reaction mixture was diluted with CH 2 Cl 2 , washed several times with saturated NaHCO3. The organic phase was dried and concentrated. The residue was purified by column chromatography (EtOAc:n-Hexane = 1: 3-1:2) to afford compound 14 (338 mg, 98%) as a white sticky solid. Rf 0.45 (EtOAc:n-Hexane = 1:2); 
1-O-Benzoyl-2-O-(6-aminohexanoyl)-scyllo-inositol (22).
A mixture of compound 21 (338 mg, 0.379 mmol) and 20 wt % Pd(OH)2/C (moisture 60%) (170 mg) in CH2Cl2: EtOH (2: 3, 5 mL) was hydrogenated under H 2 (pressure: 50 psi) for 48 h. The reaction mixture was filtered through a celite-bed and the filtrate was concentrated to afford compound 22 (140 mg, quantitative) as a white sticky solid. R f 0.12 (CH 2 Benzoyl-2-O-(6-N-Cbz-aminohexanoyl)-3,4,5,6-tetra-O-[6-[bis-(3-N,N'-di-Boc-guanidino-propyl) 
1-O-
1-O-Benzoyl-2-O-(6-aminohexanoyl)-3,4,5,6-tetra-O-[6-[bis-(3-N,N'-di-Boc-guanidino-propyl)-amino]-hexanoyl]-scyllo-inositol (25).
A mixture of compound 24 (100 mg, 0.03 mmol) in a mixed solvent of CH 2 Cl 2 :MeOH (1:9, 5 mL) was hydrogenated (40 psi) over 10% Pd/C (25 mg) at rt. After 24 h, the catalyst was filtered through a celite bed and the filtrate was evaporated to afford free amine 25 (96 mg, 99%) as a sticky solid. 
1-O-Benzoyl-2-O-[6-(N-fluoresceinyl-5-thioureido)-hexanoyl]-3,4,5,6-tetra-O-[6-[bis-(3-N,N'-di-Boc-guanidino-propyl)-amino]-hexanoyl]-scyllo-inositol (26).
To a solution of 25 (88 mg, 0.027 mmol) in a mixed solvent THF:abs. ethanol (5 mL, 2:3), were added fluorescein-5-isothiocyanate (12.7 mg, 0.032 mmol) and triethylamine (11.3 µL, 0.081 mmol). The reaction mixture was stirred for 24 h at rt in dark, concentrated, diluted with ethyl acetate, and washed with water. Organic phase was dried and concentrated. The crude product 26 (99 mg) was used in the next reaction without further purification. ),] was dissolved in sterile distilled water (1 mL) and injected into 8-week-old mice (C57BL/6) intraperitoneally. The treated mice were perfused after 20 minutes with 4% paraformaldehyde in PBS (pH 7.4). The organs were incubated overnight in 0.5 M sucrose in PBS. Placed in cryoprotectant, they were cut into 15-μm sections with cryostat, and transferred to coated glass slides. After drying at 37 o C, the sections were washed with PBS and treated with 0.3% Triton X-100 for 15 minutes at room temperature and analyzed with an Axioplan2 fluorescence imaging microscope.
Results and Discussion
All transporters used in the present studies (1-3) were prepared from the myo-inositol derivative 6, 26 essentially according to the reported procedures. [14] [15] [16] [17] For the synthesis of transporter 1, the C1-OH of compound 6 was condensed with N-Cbz protected 6-aminohexanoic acid using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 4-dimethylaminopyridine (DM-AP), and then the acetonide protecting groups were removed by treatment with EtOAc saturated with HCl (g) to provide compound 8. Exhaustive coupling of 8 with bisguanidinylated carboxylic acid 12a and 12b 15 in the presence of EDC and DMAP gave the acylated products in good yields. Removal of the N-Cbz protecting group in the side chain of the acylated products by hydrogenolysis, attachment of the fluorescent probe on the primary amino group with fluorescein-5-isothiocyanate (FITC-I), and finally removal of the Boc groups on the guanidine groups in EtOAc saturated with HCl (g) gave desired MTs 1a and 1b (Scheme 1). The scyllo-inositol based transporters 2 and 3a were similarly prepared from 13, 20 and requisite components respectively (Scheme 2 and 3). The transporters (1-3) obtained as their HCl salt were rigorously purified by medium-pressure liquid chromatography (MPLC) on a reverse phase (C8) silica gel column, and preparative high performance liquid chromatography (HPLC) on a reverse phase (C18) column when necessary. They were all satisfactorily characterized by 1 H NMR spectroscopy and MALDI-TOF mass spectral analyses. The sample purity was assessed by analytical HPLC on a ZORBAX SB-C8 reverse phase column (5 μm, 4.6 mm ID × 25 cm; flow rate 1 mL min First, the cellular uptake property of compounds 1-3 was examined in live HeLa cells by confocal laser scanning microscopy (CLSM) with FITC-labeled arginine octamer (R8-F1) as the reference. After incubation with 5.0 μM of each transporter for 10 min at 37 o C, the cells were found substantially marked with the green fluorescence. The quantitative uptake efficiencies were measured by fluorescence-activated cell-sorter (FACS) for all five transporters, and the results are summarized in Fig. 1 . The FACS analyses show that all MTs are internalized substantially better than R8-F1. The MTs with longer linker chains (1b and 2b) show more efficient uptake than the shorter chain versions (1a and 2a) as expected, and the MT with the ortholike substitution (3a) shows better uptake than the one with para-like substitution (2a). The intracellular localization patterns of all MTs (2.5 -5.0 μM) were examined without fixing in HeLa cells by co-incubating with MitoTracker Red (500 nM, Invitrogen) at 37 o C for 10 min, and the results are shown in Fig. 2 . The myo-inositol based transporters (1a and 1b) showed good localization in mitochondria (Fig. 2a) , whereas the scylloinositol based transporters (2a, 2b, and 3a) displayed little affinity toward mitochondria showing only punctate patterns with poorly defined localization. (Fig. 2b) . Previously, with the lactose-and sucrose-based transporters the lipophilicity reflected in the HPLC retention time on a reverse phase column, [28] [29] [30] appeared to be somewhat correlated to the mitochondrial affinity. 16, 17 However, the present cases show poor correlation between the HPLC-based lipophilicity and the mitochondrial localization. Instead the mitochondrial affinity appears better correlated with the stereochemistry of the scaffold; transporters 1a and 1b (myo-inositol, para-like substitution) show good affinity toward mitochondria, whereas transporters 2a and 2b with identical structures except the scaffold stereochemistry (scylloinositol, para-like), and 3a (scyllo-inositol, ortho-like) do not exhibit much affinity for mitochondria. )] was dissolved in sterile distilled water and injected intraperitoneally (ip) into 8-week-old mice (C57BL/6). After 20 min, the treated mice were perfused with 4% paraformaldehyde in phosphate buffered saline solution (PBS; pH 7.4), and the major organs (heart, spleen, liver, kidneys, lungs, and brain) were incubated overnight in a solution of 0.5 M sucrose in PBS. Placed in cryoprotectant, they were cut into 15-μm sections with a cryostat and transferred to coated glass slides. After drying at 37 o C, the sections were washed with PBS and treated with 0.3% Triton X-100 for 15 min at rt, and analyzed with an Axioplan2 fluorescence imaging microscope (Fig. 3) . Some selectivity trends in the tissue distribution are observed: 1) all transporters show a good affinity for brain; 2) myo-inositol based transporters (1a, 1b) show an affinity toward liver and spleen to a degree; 3) scyllo-inositol based transporters (2a, 2b, 3a) are much widely distributed in all organs including kidney, lung, heart, spleen and liver. It is clear that all transporters can overcome the mouse blood-brain-barrier (BBB), when given via either the ip or per oral (po) route (Fig. 1 in Supplementary Materials). 31 
Conclusion
In summary, we have prepared five G8 molecular transporters built on two stereoisomeric inositol (myo-and scyllo-) scaffolds, and examined their cellular uptake properties and the intracellular localization patterns. Transporters 1a and 1b (myo-inositol scaffold with para-like substitution) were found to target mitochondria, whereas transporters, 2a and 2b (scyllo-inositol, para-like), and 3a (scyllo-inositol, ortho-like) did not show much affinity for mitochondria. Although the mitochondrial affinity of guanidine-rich MTs generally appears to result from the subtle interplay of the number of charge (guanidine residues), geometric factors (scaffold and linker chain), and the overall lipophilicity, the present study demonstrates importance of the stereochemistry of the scaffold as a key parameter. 32 
